<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508842</url>
  </required_header>
  <id_info>
    <org_study_id>HXYT-011</org_study_id>
    <nct_id>NCT04508842</nct_id>
  </id_info>
  <brief_title>CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)</brief_title>
  <official_title>The Phase I Efficacy and Safety Clinical Study of CD19/CD22-Dual-STAR-T Cells in Relapsed and Refractory B-ALL.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Yanda Ludaopei Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Immunotech (Beijing) Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Yanda Ludaopei Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, single arm, open-lable phase I study to determine the safety and&#xD;
      efficacy of CD19/CD22-Dual-STAR-T cells in patients with refractory and relapsed B cell acute&#xD;
      leukemia .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive&#xD;
      chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion&#xD;
      of Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of&#xD;
      6E5、1E6、2E6、3E6 cells/kg.The purpose of current study is to evaluate the clinical safety and&#xD;
      efficacy of CD19/CD22-Dual-STAR-T cells therapy in patients with refractory and relapsed&#xD;
      B-ALL.Safety and efficacy of Dual-STAR-T cells therapy will be monitored. The primary&#xD;
      endpoint is the safety of Dual-STAR-T cells including the effect ratio of CRS and ICANS, ORR.&#xD;
      The secondary endpoint is the Dual-STAR-T cell proliferation ratio and Dual-STAR gene copied&#xD;
      number in peripheral blood（PB）， and progression free survival(PFS ), overall-survival(OS) and&#xD;
      duration of overall response(DOR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">November 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with adverse events.</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants with adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Remission Rate(ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>The percentage of participants who achieved complete remission(CR) and CR in over all participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proliferation ratio of Dual-STAR-T cells</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Refractory and Relapsed B Cell Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>CD19/CD22-Dual-STAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD19/CD22-Dual-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of Dual-STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 500mg/m2 for 3 days and take a rest for 2 days before infusion. Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19/CD22-Dual-STAR-T</intervention_name>
    <description>Patients with B cell acute leukemia will be enrolled, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD22-Dual-STAR-T cells.Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.</description>
    <arm_group_label>CD19/CD22-Dual-STAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 1 to 70 years.&#xD;
&#xD;
          2. Prelapsed and refractorys B-ALL at least with one of the following conditions:&#xD;
&#xD;
               -  Could not achieve CR after 2course of chemotherapy.&#xD;
&#xD;
               -  Could not achieve CR or relapse after first-line or multi-line salvage&#xD;
                  chemotherapy, or MRD≥0.1%.&#xD;
&#xD;
               -  Relapse within 12 months after first remission or MRD≥0.1%.&#xD;
&#xD;
               -  Relapse after achieved CR in allogeneic hematopoietic stem cell transplantation&#xD;
                  (HSCT), or MRD≥0.1%.&#xD;
&#xD;
               -  For Ph + patients: Failure to tolerate TKI or TKI treatment failure could be&#xD;
                  enrolled.&#xD;
&#xD;
          3. CD19 and/or CD22 positive within 3 months.&#xD;
&#xD;
          4. ECOG 0-2.&#xD;
&#xD;
          5. Estimated life expectancy ≥ 3 months.&#xD;
&#xD;
          6. Women of childbearing age must receive a pregnancy test within 7 days prior to&#xD;
             initiation of treatment and the results are negative; male and female patients with&#xD;
             fertility must use an effective contraceptive to ensure 12 months after&#xD;
             discontinuation of treatment during the study period not pregnant inside.&#xD;
&#xD;
          7. Patients who voluntarily sign informed consent and are willing to comply with&#xD;
             treatment plans, visit arrangements, laboratory tests and other research procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active infections that are difficult to control&#xD;
&#xD;
          2. HBV-DNA HCV-RNA and HIV ,either of which is positive&#xD;
&#xD;
          3. Central nervous system leukemias that is symptomatic or uncontrolled by systemic&#xD;
             chemotherapy and intrathecal chemotherapy&#xD;
&#xD;
          4. Patients are receiving anti-GVHD treatment within 4 weeks of before screening.&#xD;
&#xD;
          5. Performed major surgery within 4 weeks before screening.&#xD;
&#xD;
          6. Patients have received chemotherapy within 7 days of screening.&#xD;
&#xD;
          7. Experimental drugs were used within 4 weeks before screening.&#xD;
&#xD;
          8. Received allogeneic cell therapy within 6 weeks prior to cell infusion.&#xD;
&#xD;
          9. Patients have history of epilepsy or central nervous system diseases.&#xD;
&#xD;
         10. Severe thyroid dysfunction&#xD;
&#xD;
         11. Patients with active autoimmune disease.&#xD;
&#xD;
         12. Pregnant or lactating women.&#xD;
&#xD;
         13. The patient does not agree to use effective contraception during treatment and for the&#xD;
             following 12 months;&#xD;
&#xD;
         14. The researchers found that it was unsuitable for the recipients to be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xian Zhang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xian Zhang, PhD</last_name>
    <phone>13641041596</phone>
    <email>zhxian2@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hebei Yanda Ludaopei Hospital</name>
      <address>
        <city>Sanhe</city>
        <state>Hebei</state>
        <zip>065200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xian Zhang, PhD</last_name>
      <phone>13641041596</phone>
      <email>zhxian2@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 9, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

